A field trial to assess a blood-stage malaria vaccine

Abstract

Background: Blood-stage malaria vaccines are intended to prevent clinical disease. The malaria vaccine FMP2.1/AS02(A), a recombinant protein based on apical membrane antigen 1 (AMA1) from the 3D7 strain of Plasmodium falciparum, has previously been shown to have immunogenicity and acceptable safety in Malian adults and children.

Methods: In a double-blind, randomized trial, we immunized 400 Malian children with either the malaria vaccine or a control (rabies) vaccine and followed them for 6 months. The primary end point was clinical malaria, defined as fever and at least 2500 parasites per cubic millimeter of blood. A secondary end point was clinical malaria caused by parasites with the AMA1 DNA sequence found in the vaccine strain.

Results: The cumulative incidence of the primary end point was 48.4% in the malaria-vaccine group and 54.4% in the control group; efficacy against the primary end point was 17.4% (hazard ratio for the primary end point, 0.83; 95% confidence interval [CI], 0.63 to 1.09; P=0.18). Efficacy against the first and subsequent episodes of clinical malaria, as defined on the basis of various parasite-density thresholds, was approximately 20%. Efficacy against clinical malaria caused by parasites with AMA1 corresponding to that of the vaccine strain was 64.3% (hazard ratio, 0.36; 95% CI, 0.08 to 0.86; P=0.03). Local reactions and fever after vaccination were more frequent with the malaria vaccine.

Conclusions: On the basis of the primary end point, the malaria vaccine did not provide significant protection against clinical malaria, but on the basis of secondary results, it may have strain-specific efficacy. If this finding is confirmed, AMA1 might be useful in a multicomponent malaria vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, NCT00460525.).

Figures

Figure 1

Enrollment and Follow-up of the Study Participants.

Figure 2. Kaplan–Meier Estimates of the Cumulative Proportion of Children in the Intention-to-Treat Cohort with at Least One Episode of Clinical Malaria over Time, According to Vaccine Group

Clinical malaria was defined as a fever with a parasite density of at least 2500 parasites per cubic millimeter. Panel A shows the data for all (first or only) clinical malaria episodes. Panel B shows the data for all (first or only) clinical malaria episodes involving infection with a Plasmodium falciparum strain with an apical membrane antigen 1 (AMA1) sequence homologous to that of the vaccine strain. Immunizations were administered on study days 0, 30, and 60.

Figure 3. Geometric Mean Titers of Antibody against Apical Membrane Antigen 1 (AMA1), According to Vaccine Group

Immunizations were administered on study days 0, 30, and 60. I bars represent 95% confidence intervals.